CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

Status Completed

Clinical Trial Summary

Phase II trial to study the effectiveness of CCI-779 in treating patients who have recurrent glioblastoma multiforme. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Clinical Trial Description

OBJECTIVES:

I. Determine the efficacy of CCI-779, in terms of the percentage of patients who are progression-free at 6 months, time to progression, and time to death, in patients with recurrent glioblastoma multiforme.

II. Determine the toxic effects of this drug in these patients. III. Correlate molecular alterations in the tumors of these patients with response to treatment with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to concurrent P450 anticonvulsant use (yes vs no).

Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for 5 years and then annually for up to 10 years.

PROJECTED ACCRUAL: A total of 63 patients will be accrued for this study within 39 months. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00016328
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	May 2001

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02530502` - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma	Phase 1
Withdrawn	`NCT02194452` - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	N/A
Completed	`NCT00238303` - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	Phase 2
Completed	`NCT00049387` - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma	Phase 1
Completed	`NCT02227901` - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 1
Completed	`NCT02015819` - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	Phase 1
Active, not recruiting	`NCT02179086` - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	Phase 2
Recruiting	`NCT04573140` - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)	Phase 1
Active, not recruiting	`NCT00823797` - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma	Phase 2
Completed	`NCT00045565` - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	Phase 1
Completed	`NCT01977677` - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma	Phase 1/Phase 2
Completed	`NCT01648348` - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme	Phase 1/Phase 2
Completed	`NCT00004262` - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme	Phase 1
Terminated	`NCT01996527` - 3T MRI Biomarkers of Glioma Treatment Response	Early Phase 1
Terminated	`NCT01575275` - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme	Phase 2
Completed	`NCT01119599` - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	Phase 1
Completed	`NCT01131234` - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT01103375` - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma	Phase 1
Completed	`NCT00459381` - Pazopanib in Treating Patients With Recurrent Glioblastoma	Phase 2
Completed	`NCT00316849` - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Phase 1